Research Progress on Non-viral Nanocarrier Delivery of CRISPR/Cas9
1. College of Medicine, Hunan Normal University, Changsha 410003, Hunan, China; 2. The Center for Heart Development, College of Life Sciences, Hunan Normal University, Changsha 410081, Hunan, China; 3. Changsha Ninth Hospital, Changsha 410004, Hunan, China
Abstract：Clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) technology is currently widely used in both basic and clinical application research of medicine. Since vectors play an important role in CRISPR/Cas9 technology, further developing and optimizing vector systems is of great significance. Most of the traditional vectors are viral vectors, which have high delivery efficiency, but with defects such as limited insert size, induction of immune response, carcinogenicity, difficulty in large-scale production and even off-target. Non-viral nanocarriers can solve, to some extent, the potential toxicity and capacity limitations caused by viral vectors during gene editing, and may have broader application pros-pects. This paper reviews the non-viral nanocarriers currently used for CRISPR/Cas9 system delivery, inclu-ding main difficulties that non-viral nanocarriers may encounter in delivering CRISPR/Cas9 systems, and cor-responding solutions and strategies, in order to provide a new reference for gene therapy and drug development.
